"\\r\\n<br><p>\\n<h2 class=\\"intro\\">\\nThe development of the vaccine was supported by DBT-BIRAC.\\n<\\\/h2>\\n<\\\/p><div id=\\"content-body-14269002-35898374\\">\\n<p>Bharat Biotech\\u2019s BBV154 intranasal vaccine has become the first of its kind to receive the regulatory approval for Phase 2\\\/3 trials, according to a release issued by the Ministry of Science and Technology on Friday.<\\\/p><p>\\u201cThis is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. The Company has in-licensed technology from Washington University in St Louis, USA,\\u201d said the release.<\\\/p><p>The development of the vaccine was supported by the Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC), the release stated.<\\\/p><p>As per information released by the Ministry Phase 1 Clinical trial has been completed in age groups ranging \\u226518 to \\u226460 years.<\\\/p><p>\\u201cThe Company reports that the doses of the vaccine administered to healthy volunteers in the Phase I clinical trial, has been well tolerated. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level of neutralizing antibodies in animal studies,\\u201d noted the release.<\\\/p><p>Renu Swarup, Secretary, DBT and Chairperson, BIRAC, said the department, through Mission COVID Suraksha, was committed to developing safe and efficacious COVID-19 vaccines.<\\\/p>\\n<\\\/div>\\r\\n\\r\\n<br><a href=\\"https:\\\/\\\/www.thehindu.com\\\/news\\\/national\\\/bharat-biotechs-nasal-covid-19-vaccine-gets-nod-for-phase-23-trial\\\/article35898374.ece\\">Source link <\\\/a>"